anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hip fractures are common orthopaedic problem especially in elderly population which is associated with significant morbidity and mortality. Early surgical reduction and fixation is the preferred treatment in most patients. Significant pain, if inadequately controlled, can impair early rehabilitation and functional recovery and can reduce patient satisfaction after surgery . Combinations of systemic analgesics, intra-articular injection, and neuraxial and peripheral nerve blocks should be considered as the integral components of the perioperative pain management plan. Among these, intra-articular local anaesthetic injections have been shown to play a potential role in providing analgesia after hip arthroplasty. The risks of this procedure include hematoma, nerve damage, local anaesthetics toxicity, intravenous injection of local anesthetics and septic osteoarthritis, but their occurrence is very rare. Several peripheral nerve blocks, including fascia iliaca block, femoral block (FB), and some interfascial plane blocks such as quadratus lumborum block (QLB), have also been suggested to decrease postoperative pain and opioid use. Lumbar plexus block/psoas compartment block is a technically difficult deep block that requires greater skill and hence can be time consuming. The lumbar paravertebral region is highly vascular and non-compressible. Hence, patients on anti-coagulation are at high risk for bleeding complications. There is also high risk of unintentional neuraxial block or inadvertent intravascular injection with local anaesthetic systemic toxicity. Some nerve branches responsible for hip joint innervation may not be blocked by QLB, which should be taken into consideration while using these blocks for hip fracture. High-volume suprainguinal fascia iliaca block and traditional fascia iliaca block have also been reported to be associated with a significant incidence of muscle weakness and to predispose the patient to fall. The anterior hip capsule is innervated by the obturator nerve (ON), accessory obturator nerve (AON), and femoral nerve (FN) as reported by previous anatomic studies. The anterior capsule is the most richly innervated section of the joint, suggesting these nerves should be the main targets for hip analgesia. Femoral block (FB) does not block the AON or the articular branches of the ON. Also, femoral nerve block accompanied by decreasing the strength of quadriceps muscles. Pericapsular nerve group (PENG) block was described in 2018 and reported that it was successfully used for postoperative pain management in hip surgery. The PENG block is a technique that involves deposition of local anaesthetic in the musculofascial plane between the psoas muscle and the superior pubic ramus for the blockade of the articular branches of the FN, ON and AON that provide sensory innervation to the anterior hip capsule.
Efficacy of low-frequency (1hz), inhibitory rTMS will be examined in rehabilitation of acquired aphasia. Two cortical sites will be targeted: Right-hemispheric homologues of Broca's and Wernicke's areas. In other words, right frontal and right temporal sites will be targeted.

In addition to cognitive screening prior to onset of rTMS, language assessments will be conducted before, during and after the intervention. The language assessment will be conducted using the Turkish Aphasia Language Assessment Test (ADD) and sets of pictures used to assess naming performance. ADD will be carried out before and after the intervention. Six picture sets will be used, one at baseline, four on different days during the intervention, and the last one immediately after the last day of the intervention. Cognitive screening will be conducted at baseline using the digit span test and Raven's colored progressive matrices. In addition, a pre- and post-treatment eyetracking-while-listening experiment will be conducted to investigate morphosyntactic processing in Turkish and to examine whether the two brain stimulation interventions differentially affect online (dynamic, time-dependent) measures of morphosyntactic processing. The eyetracking paradigm will request the participants to listen to Turkish sentences varying in morphosyntactic complexity (canonical versus noncanonical sentences) and to look at the picture (out of two pictures presented on the screen) corresponding to the sentence they are listening to.
After whitening in-office bleaching, the group was treated with desensitization to 10% strontium chloride. Subsequently, a laser tip was positioned at two points (apical and cervical), without emitting light (placebo).
OSA patients who are currently treated with PAP for their OSA (with AHI of previous sleep study \> 10 events/hr). In this group, patients will learn and practice upper airway muscle exercise for six weeks.
Includes age group 41-50 with a cap at 40 subjects. This is a retrospective, observational study.
A polysaccharide having anti-cancer activity is a solid, water-soluble, amorphous substance which is non-hygroscopic, and non-dialysable; has an acetyl derivative of formula (C30H40O20)n and is hydrolysable by heating with N-sulphuric acid to cerabinose, galactose and xylose in a molecular ratio of 1:1:1, and a small amount of uronic acid.  The polysaccharide and its acetyl derivative give the infra-red absorption spectra shown in Figs. 1 and 2 respectively (not shown).  The polysaccharide or material containing it may be prepared by extracting the leaves and/or stems of Gramineae, e.g. bamboo or bamboo grass, with hot water e.g. at 60-100 DEG  C.  An alkaline substance may be added during extraction to maintain the extract neutral.  The extract may then be purified to give the polysaccharide by acidifying to pH 3-4, removing the precipitate so formed and subjecting the acidified solution to one or more steps of dialysis, salting out, treatment with ion-exchange resin and treatment with lead acetate.  The polysaccharide or material containing it may also be obtained by diluting molasses with water, acidifying the solution to pH 3-4, removing the precipitate so formed and subjecting the acidified solution to dialysis and/or salting out to produce a polysaccharide-containing material and then, if desired, purifying the solution to give the polysaccharide.  The polysaccharide or derivatives thereof are incorporated into pharmaceutical compositions (Division A5).ALSO:Pharmaceutical compositions having anti-cancer activity comprise a carrier and, as active ingredient, a polysaccharide which is hydrolysable by N sulphuric acid to xylose, arabinose, galactose (molar ratio 1:1:1) and a small amount of uronic acid, gives infra red absorption spectra as in Fig. 1 (not shown), and yields an acetyl derivative of formula (C30 H40 O20)n which gives infra-red absorption spectra as in Fig 2 (not shown).  The polysaccharide may be extracted from Graminase or from molasses.  The composition may be made up in the form of tablet, pill, powder, sachet or encapsulated powder for oral administration or in the form of a steril injectable solution or suspension for parentral administration.
The total planned enrollment for this study is up to approximately 52 patients for Part 1 (dose-escalation) and Part 2 (dose expansion). Up to 18 patients will be enrolled in Part 1 (depending on dose-escalation) and 40 patients in dose expansion in Part 2. The 6 patients evaluated for dosimetry in Part 1 will also be evaluated in part 2.
Stress, obesity, hormonal changes, and aging have been connected to cellulite aggravation resulting in skin dimpled appearance, a very common painless skin disorder with a female preponderance. Several Apiaceae plants have been traditionally used for cosmetic applications. However, their screening for anti-cellulite potential has not been deeply investigated. In this work, UPLC-HRMS/MS coupled with molecular networking was employed to glean a holistic overview of the chemodiversity of the metabolome of nine Apiaceae fruits. Additionally, the extracts were screened for in vitro antioxidant and anti-cellulite activities. Apium graveolens and Petroselinum crispum revealed excellent free radical scavenging activity, remarkably increased lipolysis, and decreased adipogenesis. Furthermore, apigenin and its glycosides were identified to be the major components in both extracts, which might be responsible for the antioxidant activity and anti-cellulite potential. Conclusively, these results signify the potent antioxidant and anti-cellulite properties of A. graveolens and P. crispum fruit extracts, holding potential for the development of plant derived products for cellulite management.
This group is defined according to the following radiographic parameter: LCE angle \> 39°. The data was obtained from a retrospective study.
A healthy diet is an essential factor for healthy ageing. Previous studies of omega-3 polyunsaturated fatty acids (n-3 PUFAs) intake have shown beneficial actions on a range of human health conditions. The influence of n-3 PUFAs on cognition throughout the lifespan is particularly apparent, with beneficial effects documented on cognitive development in infants and children, cognitive performance in young adults, and to slow age-related cognitive impairment in older adults. Despite these positive findings, there has been little consideration of the influence of n-3-PUFAs on cognition in adolescence. Adolescence is characterized by profound brain development, with brain areas such as the prefrontal cortex continuing to mature into the late twenties). In this period of brain development, the basis is laid for executive functions (e.g., shifting, updating, and short-term memory), among others. Optimal development of the prefrontal cortex is very important, as the executive functions have been related to academic achievements. The positive effects from n-3 PUFAs on cognition, if translated to adolescents, would be of clear practical and theoretical importance, particularly in an academic context.

￼

This project will examine the relationship between supplementation with a commercially available, plant-derived, omega-3 intervention and cognitive performance in adolescent participants aged 13-14 years. In a randomized, placebo-controlled, double-blind, parallel-group clinical trial, we will examine the effect of 16 weeks repeated daily dosing of Juice PLUS+® OMEGA (or matched placebo) on a wide range of cognitive processes (measured using a battery of computer-based cognitive tests). Changes in cognitive performance will be mapped both to changes in omega-3 index (O3I) of our participants (measured using dried blood spots obtained via finger prick) and to changes in brain activity (measured using electrodes placed on the scalp, in a subset of participants). Participants will attend the Department on 3 separate occasions. At an initial screening visit, participants will practice the cognitive tests and provide a 3-day food diary as a measure of habitual diet. Participants will then attend a baseline test visit, where they will perform the cognitive tests and receive a 16-week supply of capsules (either placebo or active treatment) to be taken daily. After the 16 weeks, the participants will attend a post-intervention test day where they will perform the cognitive tests for a final time. Finger prick blood spot samples will be taken at each of the 3 visits.
Indomethacin cannot be considered a simple analgesic and should not be used in conditions other than those recommended under INDICATION AND USAGE.

Indomethacin is a non-steroidal anti-inflammatory indole derivative designated chemically as 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid. Indomethacin is practically insoluble in water and sparingly soluble in alcohol. It has a pKa of 4.5 and is stable in neutral or slightly acidic media and decomposes in strong alkali. The structural formula is:

M.W. 357.80 C19H16ClNO4

Each extended-release capsule, for oral administration contains 75 mg of indomethacin. In addition, each capsule contains the following inactive ingredients: ammonia, black iron oxide, butyl alcohol, corn starch, dehydrated alcohol, FD&C Blue No. 1, FD&C Green No. 3, FD&C Yellow No. 5, FD&C Red No. 40, gelatin, isopropyl alcohol, lactose monohydrate, potassium hydroxide, povidone, propylene glycol, shellac, sucrose and talc.

This Product meets the USP Drug Release Test 2 Specifications.
The aim of this study was to determine the possible therapeutic effect of chlorogenic acid (CGA) on cisplatin (CDDP)-induced ovarian damage in rats. Rats were first exposed to CDDP (5 mg/kg) and then treated CGA (1.5 and 3 mg/kg) for three days. Oxidative stress (OS), inflammation and apoptosis markers were determined using spectrophotometric methods. Ovarian tissues were also evaluated histologically. The levels of OS, inflammation and apoptosis biomarkers increased by CDDP administration (p < 0.05). Treatments with CGA significantly alleviated these markers dose-dependently (p < 0.05). These data reveal that CGA may exert an ovoprotective effect by reducing pro-inflammatory mediators and enhancing antioxidant status in ovarian tissue.
CircRNAs have been found to participate in the progression of various tumors. In the present study, we aimed to clarify the role of hsa_circ_0092355 in papillary thyroid cancer (PTC) cell development. RT-qPCR was used to determine the expression of hsa_circ_0092355, miR-543, and PDE5A. PTC cell proliferation was ascertained via a cell colony formation assay and the CCK-8 test. Western blotting was performed to examine the expression levels of PDE5A and apoptosis-associated proteins (Bcl-2 and Bax) in PTC cells. A scratch wound assay was performed to measure the migration of PTC cells. A mouse xenograft test was performed to assess the effects of hsa_circ_0092355 in vivo. RIP and dual-luciferase reporter assays confirmed the association between miR-543 and hsa_circ_0092355 or PDE5A. Associations between miR-543, hsa_circ_0092355, and PDE5A were evaluated using Pearson's correlation coefficient. Upregulation of hsa_circ_0092355 was observed in PTC tissues. The hsa_circ_0092355 knockdown blocked the proliferation and migration of PTC cells and induced apoptosis. Moreover, hsa_circ_0092355 knockdown blocked PTC xenograft tumor growth in vivo. The miR-543 inhibitor could reverse the changes induced by hsa_circ_0092355 knockdown by hsa_circ_0092355 targeting miR-543. Furthermore, miR-543 suppresses PTC progression by downregulating PDE5A expression. Our findings suggest that the PTC tumor promoter hsa_circ_0092355 may promote carcinogenesis by controlling the miR-543/PDE5A pathway.
Recruitment and informed consent procedure for blood sampling to conduct immunological testing. In addition a questionnaire on QOL (SF-12) will be used to evaluate the most actual quality of life of these patients.
Renal function should be evaluated in all patients prior to initiation of ribavirin by estimating the patient's creatinine clearance. 

A clinical trial evaluated treatment with ribavirin and peginterferon alfa-2a in 50 CHC subjects with moderate (creatinine clearance 30 to 50 mL/min) or severe (creatinine clearance less than 30 mL/min) renal impairment or end stage renal disease (ESRD) requiring chronic hemodialysis (HD). In 18 subjects with ESRD receiving chronic HD, ribavirin was administered at a dose of 200 mg daily with no apparent difference in the adverse event profile in comparison to subjects with normal renal function. Dose reductions and temporary interruptions of ribavirin (due to ribavirin-related adverse reactions, mainly anemia) were observed in up to one-third ESRD/HD subjects during treatment; and only one-third of these subjects received ribavirin for 48 weeks. Ribavirin plasma exposures were approximately 20% lower in subjects with ESRD on HD compared to subjects with normal renal function receiving the standard 1000/1200 mg ribavirin daily dose. 

Subjects with moderate (n=17) or severe (n=14) renal impairment did not tolerate 600 mg or 400 mg daily doses of ribavirin, respectively, due to ribavirin-related adverse reactions, mainly anemia, and exhibited 20% to 30% higher ribavirin plasma exposures (despite frequent dose modifications) compared to subjects with normal renal function (creatinine clearance greater than 80 mL/min) receiving the standard dose of ribavirin. Discontinuation rates were higher in subjects with severe renal impairment compared to that observed in subjects with moderate renal impairment or normal renal function. Pharmacokinetic modeling and simulation indicate that a dose of 200 mg daily in patients with severe renal impairment and a dose of 200 mg daily alternating with 400 mg the following day in patients with moderate renal impairment will provide plasma ribavirin exposure similar to patients with normal renal function receiving the approved regimen of ribavirin. These doses have not been studied in patients [see Dosage And Administration (2.4), and Clinical Pharmacology (12.3)].

Based on the pharmacokinetic and safety results from this trial, patients with creatinine clearance less than or equal to 50 mL/min should receive a reduced dose of ribavirin; and patients with creatinine clearance less than 30 mL/min should receive a reduced dose of peginterferon alfa-2a. The clinical and hematologic status of patients with creatinine clearance less than or equal to 50 mL/min receiving ribavirin should be carefully monitored. Patients with clinically significant laboratory abnormalities or adverse reactions which are persistently severe or worsening should have therapy withdrawn [see Dosage And Administration (2.4), Clinical Pharmacology (12.3), and PEGINTERFERON ALFA-2A Package Insert].
PURPOSE: A composition containing Dioscorea opposita Thunb. fermentation is prevent and treat gastrointestinal diseases and to protect intestine from acute gastritis. CONSTITUTION: A composition for preventing or treating gastrointestinal diseases contains Dioscorea opposita Thunb. fermentation. The fermentation is prepared by lactic acid bacteria such as Lactobacillus ps. or streptococcus sp. The fermentation is prepared from raw Dioscorea opposita Thunb. powder or hot water extract by Lactobacillus bulgaricus or Streptococcus thermophilus. A supplementary health food for preventing or treating intestinal diseases contains the fermentation. The supplementary health food is manufactured in the form of beverage, tablet, capsule, powder, granule, liquid or pill.
The subject of the present invention is to provide a composition that is capable of suppressing muscle reduction in cancer patients and then is useful in prolonging the life prognosis and improving QOL of the cancer patients. The composition for suppressing muscle mass reduction of a cancer patient according to the present invention is, for example, a high fat low carbohydrate composition comprising a lipid, a protein and a saccharide. The lipid is a fatty acid triglyceride comprising at least one of a long chain fatty acid triglyceride and a medium chain fatty acid triglyceride. Besides, in the invention, the wording "composition for suppressing muscle mass reduction in cancer patients" means literally as the meanings shown by the words; namely, a composition that suppresses a decrease in muscle mass of a cancer patient, however, it can also be read as a composition for alleviating the decrease rate in muscle mass of cancer patients. Further, in the invention, the composition for suppressing muscle mass reduction in cancer patients may be composed of merely a protein, a lipid and a carbohydrate. In addition, the term "composition" as used in the invention comprises a substances that can be ingested by animals (including humans), comprising preparations such as liquid foods and food additives, foods/beverages(excluding animals and plants themselves), and foods/beverages composition(including processed foods and drinks).
The present invention discloses fusion protein, a coding gene and application thereof. The present invention has the purpose of providing fusion protein and a coding gene and application thereof for preparing medicine for treating diseases caused by the abnormal generation of new blood vessels. The fusion protein is protein having an SEQ ID No. 2 amino acid residue sequence in a sequence table or protein which has the same activity as that of the amino acid residue sequence of the SEQ ID No. 2, is derived from the SEQ ID No. 2 and is formed by means that the amino acid residue sequence of the SEQ ID No. 2 is replaced, deleted or added by one or a plurality of amino acid residues. As proved by a cell experiment, the fusion protein of the present invention can be used for effectively inhibiting the proliferation of vascular endothelial cells so as to inhibit the neogenesis of blood vessels to further inhibit tumor growth. The fusion protein can be used for preparing medicine for treating diseases (such as tumor) caused by the abnormal generation of the new blood vessels. The fusion protein has wide industrial application prospects.
Gabapentin capsules USP are supplied as imprinted hard shell capsules containing 300 mg of gabapentin. In addition, each capsule contains the following inactive ingredients: corn starch, FD&C Red No. 3, FD&C Yellow No. 6, gelatin, talc, and titanium dioxide. The imprinting ink contains black iron oxide and shellac and may contain antifoam DC, propylene glycol, and soya lecithin.

Gabapentin is described as 1-(aminomethyl)cyclohexaneacetic acid. The structural formula of gabapentin is:

C9H17NO2 M.W. 171.24

Gabapentin is a white to off-white crystalline solid with a pKa1 of 3.7 and a pKa2 of 10.7. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is -1.25.
Thirty minutes before initiation of ischemia the surgeon was instructed to notify the anesthesiologist. At this single time point, propofol infusion was stopped and substituted with the volatile anesthetic desflurane to achieve a Minimum Alveolar Concentration of 1. The procedure included a 5-minute induction of desflurane, a 20-minute preconditioning and a 5-minute washout period when propofol was reintroduced and desflurane stopped.
A computer-implemented method is for creating an individual gene panel plan. The method includes receiving and/or determining a plurality of clinical trials. In this case, each clinical trial of the plurality of clinical trials includes a molecular genetic inclusion criterion. The molecular genetic inclusion criterion relates in this case to gene information relevant to the respective clinical trial. The method further includes determining, for each clinical trial of the plurality of clinical trials, at least one genomic region to which the gene information of the clinical trial relates. The method further includes creating the gene panel plan based on the genomic regions determined in respect of the plurality of clinical trials. The method further includes providing the gene panel plan.
PURPOSE:To obtain a mutagenicity inhibitor, containing a water-insoluble compound formed by peroxidase reaction of a compound having a phenylpropane skeleton as an active ingredient. CONSTITUTION:A mutagenicity inhibitor obtained by dissolving a compound selected from isoeugenol, coniferyl alcohol and ferulic acid in a water-miscible organic solvent in an amount of 5-50 times based on the compound, then mixing the above-mentioned solution with water adjusted to pH 4-9 (preferably phosphoric acid buffer solution at pH 6-7 in 10-100mM concentration) in an amount of 5-100 times based on the afore-mentioned solution and adding peroxidase in an amount of 0.5-10pts. based on 100pts.wt. above-mentioned compound and 30% hydrogen peroxide in an amount of 5-200pts.wt. based on 100pts.wt. above-mentioned compound while dripping or at a time, stirring and reacting the reaction mixture at room temperature for >=1hr, recovering a water-insoluble compound by centrifugation or filtration, washing the recovered compound with water and drying the washed compound. The afore- mentioned water-insoluble substance is capable of inhibiting mutagenicity by direct mutagen without requiring metabolic activation and important for preventing carcinogenesis.